<DOC>
	<DOCNO>NCT03072056</DOCNO>
	<brief_summary>- To evaluate pharmacokinetic ( PK ) profile MIN-101 metabolite extensive ( EM ) poor ( PM ) metabolizers - To evaluate relationship plasma level MIN-101 change QT/QTcF interval - To evaluate safety tolerability MIN-101 .</brief_summary>
	<brief_title>A Pharmacokinetic Study MIN-101 Its Metabolites Healthy Subjects Compare MIN-101 Poor Extensive Metabolizers</brief_title>
	<detailed_description />
	<criteria>1 . Confirmed CYP2D6 extensive poor metabolizer genotype 2 . Subject give voluntary write informed consent performance study related procedure 3 . Subject must 18 45 year age , inclusive 4 . Subject must healthy male female indicate follow : Clinical chemistry , hematology , urinalysis test must within normal , allowable limit ( range , exception potassium , magnesium , calcium , must consider clinically significant exclusionary ) perform within 21 day receive first dose study drug Body mass index 18 30 kg/m2 Normal vital sign 5 minute rest supine position stand position 5 minute rest supine position : 95 mm Hg &lt; systolic blood pressure &lt; 140 mm Hg 50 mm Hg &lt; diastolic blood pressure &lt; 90 mm Hg 50 bpm &lt; heart rate &lt; 90 bpm Systolic blood pressure decrease le 20 mm Hg within 3 minute stand Diastolic blood pressure decrease le 10 mm Hg within 3 minute stand Normal 12lead automatic ECG : 120 m &lt; PR &lt; 210 m , QRS &lt; 120 m , QTc ( Fridericia ) ≤ 430 msec male ≤ 440 m female 5 . Agree abstain medication ( except allow birth control # 5 ) , include nonprescription prescription medication ( include vitamin natural herbal remedy , e.g . St. John 's Wort ) 21 day first study day discharge study ( end post study medical ) . 6 . Subject agree use adequate method birth control ( exclude oral hormonal contraception ) . Subjects sexually active must use , partner , 2 approve method highly effective contraception time study drug administration 90 day last dose study drug . 1 . A history clinically significant gastrointestinal disease , especially peptic ulceration , gastrointestinal bleeding , ulcerative colitis , Crohn 's disease Irritable Bowel Syndrome ; renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic psychiatric disease , especially past history depression , suicidal ideation suicide attempt , cardiovascular disease , condition , opinion principle investigator , would jeopardize safety subject impact validity study result 2 . Acute diarrhea constipation 7 day predict first study day . If screen occur &gt; 7 day first study day , criterion determine first study day . 3 . Subject donate blood within 90 day plasma within 30 day study dose 4 . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 Unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 5 . Subject borderline long QTc interval Fridericia correction method , define screening reading &gt; 430 msec male &gt; 440 female personal familial history long QT syndrome 6 . Subject participate clinical trial within 90 day prior study initiation 7 . Females child bear potential pregnant , breast feeding either surgically sterile , postmenopausal , sexually active use acceptable form contraception 8 . Subject use overthecounter ( OTC ) medication , dietary herbal supplement , include vitamin , within 21 day prior study entry 9 . Subject use prescription medication within 21 day prior Day 1 10 . Subject treat known CYP2D6 CYP3A4 enzymes alter drug within 30 day prior study 11 . Subject smoke used tobacco product within 2 month prior study 12 . Subject sought advice refer GP counselor abuse misuse alcohol , nonmedical drug , medicinal drug substance abuse , e.g . solvent 13 . Subject positive blood screen HIV , Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody and/or positive urine screen drug abuse positive alcohol breath test screening , history positive urine drug abuse screen 14 . Any current previous use drug opiate , cocaine , ecstasy , intravenous amphetamine Subjects admit occasional past use cannabis exclude long negative drugsofabuse test abstinent cannabis use least 3 month 15 . Subject uncontrolled intercurrent illness ( i.e. , active infection ) 16 . Subject major surgery within 28 day study entry , 12 month prior study gastrointestinal surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>